Virios Therapeutics, Inc. announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (?PASC?). The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3549 USD | -4.75% | -13.75% | -38.28% |
May. 09 | Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.28% | 6.83M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- VIRI Stock
- News Virios Therapeutics, Inc.
- Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid